Related Experiment Video
Updated: Sep 2, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Complement activation in COVID-19 and targeted therapeutic options: A scoping review
Endry Hartono Taslim Lim1, Rombout Benjamin Ezra van Amstel2, Vieve Victoria de Boer3
1Amsterdam UMC location University of Amsterdam, Department of Intensive Care Medicine, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Laboratory of Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Amsterdam, the Netherlands; Amsterdam UMC location University of Amsterdam, Department of Neurology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Neuroscience, Amsterdam, the Netherlands.
Complement activation significantly contributes to Coronavirus disease 2019 (COVID-19) severity. Inhibiting C5 and C5a shows promise, but further clinical trials are needed to confirm effectiveness in treating COVID-19.
Area of Science:
- Immunology
- Virology
- Pathology
Background:
- Growing evidence links complement system activation to COVID-19 pathogenesis.
- The complement system's role in disease severity and mortality is increasingly recognized.
Purpose of the Study:
- To provide a comprehensive overview of complement activation in COVID-19.
- To identify promising therapeutic targets within the complement system for COVID-19.
Main Methods:
- Systematic scoping review of 157 articles from PubMed, EMBASE, and Cochrane.
- Analysis of histopathological, preclinical, multiomics, observational, and clinical interventional studies.
Main Results:
- Evidence confirms complement activation via all three pathways in COVID-19.
- Complement activation correlates with increased disease severity and mortality.
- C5 and C5a inhibition emerged as the most promising therapeutic strategies.
Conclusions:
- Targeting the complement system is a potential therapeutic avenue for COVID-19.
- Further adequately powered, double-blind randomized controlled trials are essential to validate complement inhibition therapies.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
06:03Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024